Selected research
Industry Research
Paediatric Influenza Prevention Industry Research Report 2026
Market perspective
The global Paediatric Influenza Prevention market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Paediatric Influenza Prevention is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Paediatric Influenza Prevention is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Paediatric Influenza Prevention is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Paediatric Influenza Prevention include Sanofi, Jiangsu GDK, GSK, Viatris, Sinovac, KM Biologics, Hulan Bio, CSL and CCBIO, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Paediatric Influenza Prevention market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Paediatric Influenza Prevention Market by Company
Sanofi
Jiangsu GDK
GSK
Viatris
Sinovac
KM Biologics
Hulan Bio
CSL
CCBIO
BCHT
AstraZeneca
Paediatric Influenza Prevention Segment by Type
Nasal Spray
Injection
Paediatric Influenza Prevention Segment by Application
Public
Private
Paediatric Influenza Prevention Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Paediatric Influenza Prevention market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Paediatric Influenza Prevention and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Paediatric Influenza Prevention.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Paediatric Influenza Prevention manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Paediatric Influenza Prevention by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Paediatric Influenza Prevention in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Nasal Spray
- Injection
Applications
- Public
- Private
Companies covered
- Sanofi
- Jiangsu GDK
- GSK
- Viatris
- Sinovac
- KM Biologics
- Hulan Bio
- CSL
- CCBIO
- BCHT
- AstraZeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Paediatric Influenza Prevention Market Size (2021-2032)
- 2.2.2 Global Paediatric Influenza Prevention Sales (2021-2032)
- 2.2.3 Global Paediatric Influenza Prevention Market Average Price (2021-2032)
- 2.3 Paediatric Influenza Prevention by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Nasal Spray
- 2.3.3 Injection
- 2.4 Paediatric Influenza Prevention by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Public
- 2.4.3 Private
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Paediatric Influenza Prevention Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Paediatric Influenza Prevention Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Paediatric Influenza Prevention Revenue of Manufacturers (2021-2026)
- 3.4 Global Paediatric Influenza Prevention Average Price by Manufacturers (2021-2026)
- 3.5 Global Paediatric Influenza Prevention Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Paediatric Influenza Prevention, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Paediatric Influenza Prevention, Product Type & Application
- 3.8 Global Manufacturers of Paediatric Influenza Prevention, Established Date
- 3.9 Global Paediatric Influenza Prevention Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Paediatric Influenza Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Paediatric Influenza Prevention Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Jiangsu GDK
- 4.2.1 Jiangsu GDK Company Information
- 4.2.2 Jiangsu GDK Business Overview
- 4.2.3 Jiangsu GDK Paediatric Influenza Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Jiangsu GDK Paediatric Influenza Prevention Product Portfolio
- 4.2.5 Jiangsu GDK Recent Developments
- 4.3 GSK
- 4.3.1 GSK Company Information
- 4.3.2 GSK Business Overview
- 4.3.3 GSK Paediatric Influenza Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GSK Paediatric Influenza Prevention Product Portfolio
- 4.3.5 GSK Recent Developments
- 4.4 Viatris
- 4.4.1 Viatris Company Information
- 4.4.2 Viatris Business Overview
- 4.4.3 Viatris Paediatric Influenza Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Viatris Paediatric Influenza Prevention Product Portfolio
- 4.4.5 Viatris Recent Developments
- 4.5 Sinovac
- 4.5.1 Sinovac Company Information
- 4.5.2 Sinovac Business Overview
- 4.5.3 Sinovac Paediatric Influenza Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sinovac Paediatric Influenza Prevention Product Portfolio
- 4.5.5 Sinovac Recent Developments
- 4.6 KM Biologics
- 4.6.1 KM Biologics Company Information
- 4.6.2 KM Biologics Business Overview
- 4.6.3 KM Biologics Paediatric Influenza Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 KM Biologics Paediatric Influenza Prevention Product Portfolio
- 4.6.5 KM Biologics Recent Developments
- 4.7 Hulan Bio
- 4.7.1 Hulan Bio Company Information
- 4.7.2 Hulan Bio Business Overview
- 4.7.3 Hulan Bio Paediatric Influenza Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hulan Bio Paediatric Influenza Prevention Product Portfolio
- 4.7.5 Hulan Bio Recent Developments
- 4.8 CSL
- 4.8.1 CSL Company Information
- 4.8.2 CSL Business Overview
- 4.8.3 CSL Paediatric Influenza Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 CSL Paediatric Influenza Prevention Product Portfolio
- 4.8.5 CSL Recent Developments
- 4.9 CCBIO
- 4.9.1 CCBIO Company Information
- 4.9.2 CCBIO Business Overview
- 4.9.3 CCBIO Paediatric Influenza Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 CCBIO Paediatric Influenza Prevention Product Portfolio
- 4.9.5 CCBIO Recent Developments
- 4.10 BCHT
- 4.10.1 BCHT Company Information
- 4.10.2 BCHT Business Overview
- 4.10.3 BCHT Paediatric Influenza Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 BCHT Paediatric Influenza Prevention Product Portfolio
- 4.10.5 BCHT Recent Developments
- 4.11 AstraZeneca
- 4.11.1 AstraZeneca Company Information
- 4.11.2 AstraZeneca Business Overview
- 4.11.3 AstraZeneca Paediatric Influenza Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 AstraZeneca Paediatric Influenza Prevention Product Portfolio
- 4.11.5 AstraZeneca Recent Developments
5 Global Paediatric Influenza Prevention Market Scenario by Region
- 5.1 Global Paediatric Influenza Prevention Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Paediatric Influenza Prevention Sales by Region: 2021-2032
- 5.2.1 Global Paediatric Influenza Prevention Sales by Region: 2021-2026
- 5.2.2 Global Paediatric Influenza Prevention Sales by Region: 2027-2032
- 5.3 Global Paediatric Influenza Prevention Revenue by Region: 2021-2032
- 5.3.1 Global Paediatric Influenza Prevention Revenue by Region: 2021-2026
- 5.3.2 Global Paediatric Influenza Prevention Revenue by Region: 2027-2032
- 5.4 North America Paediatric Influenza Prevention Market Facts & Figures by Country
- 5.4.1 North America Paediatric Influenza Prevention Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Paediatric Influenza Prevention Sales by Country (2021-2032)
- 5.4.3 North America Paediatric Influenza Prevention Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Paediatric Influenza Prevention Market Facts & Figures by Country
- 5.5.1 Europe Paediatric Influenza Prevention Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Paediatric Influenza Prevention Sales by Country (2021-2032)
- 5.5.3 Europe Paediatric Influenza Prevention Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Paediatric Influenza Prevention Market Facts & Figures by Country
- 5.6.1 Asia Pacific Paediatric Influenza Prevention Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Paediatric Influenza Prevention Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Paediatric Influenza Prevention Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Paediatric Influenza Prevention Market Facts & Figures by Country
- 5.7.1 South America Paediatric Influenza Prevention Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Paediatric Influenza Prevention Sales by Country (2021-2032)
- 5.7.3 South America Paediatric Influenza Prevention Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Paediatric Influenza Prevention Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Paediatric Influenza Prevention Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Paediatric Influenza Prevention Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Paediatric Influenza Prevention Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Paediatric Influenza Prevention Sales by Type (2021-2032)
- 6.1.1 Global Paediatric Influenza Prevention Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Paediatric Influenza Prevention Sales Market Share by Type (2021-2032)
- 6.2 Global Paediatric Influenza Prevention Revenue by Type (2021-2032)
- 6.2.1 Global Paediatric Influenza Prevention Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Paediatric Influenza Prevention Revenue Market Share by Type (2021-2032)
- 6.3 Global Paediatric Influenza Prevention Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Paediatric Influenza Prevention Sales by Application (2021-2032)
- 7.1.1 Global Paediatric Influenza Prevention Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Paediatric Influenza Prevention Sales Market Share by Application (2021-2032)
- 7.2 Global Paediatric Influenza Prevention Revenue by Application (2021-2032)
- 7.2.1 Global Paediatric Influenza Prevention Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Paediatric Influenza Prevention Revenue Market Share by Application (2021-2032)
- 7.3 Global Paediatric Influenza Prevention Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Paediatric Influenza Prevention Value Chain Analysis
- 8.1.1 Paediatric Influenza Prevention Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Paediatric Influenza Prevention Production Mode & Process
- 8.2 Paediatric Influenza Prevention Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Paediatric Influenza Prevention Distributors
- 8.2.3 Paediatric Influenza Prevention Customers
9 Global Paediatric Influenza Prevention Analyzing Market Dynamics
- 9.1 Paediatric Influenza Prevention Industry Trends
- 9.2 Paediatric Influenza Prevention Industry Drivers
- 9.3 Paediatric Influenza Prevention Industry Opportunities and Challenges
- 9.4 Paediatric Influenza Prevention Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst